Apixaban - CAS 503612-47-3
Catalog number: B0084-069824
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Factor Xa
Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-069824 5 g $288 In stock
Bulk Inquiry
BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
Canonical SMILES:
1.Atrial fibrillation in dialysis patients: time to abandon warfarin?
Brancaccio D1, Neri L2, Bellocchio F2, Barbieri C2, Amato C2, Mari F2, Canaud B3, Stuard S3. Int J Artif Organs. 2016 Apr 9:0. doi: 10.5301/ijao.5000487. [Epub ahead of print]
Atrial fibrillation (AF) is a frequent clinical complication in dialysis patients, and warfarin therapy represents the most common approach for reducing the risk of stroke in this population. However, current evidence based on observational studies, offer conflicting results, whereas no randomized controlled trials have been carried out so far. Additionally, many clinicians are wary of the possible role of warfarin as vascular calcification inducer and its potential to increase the high risk of bleeding among patients on dialysis. Ideally the most promising therapy would be based on direct inhibitors of factor IIa or Xa; however, at the moment, none of these drugs can be safely prescribed in dialysis patients, because of their potentially dangerous accumulation, and the lack of sufficient experience with apixaban or rivaroxaban, two drugs showing a favorable pharmacokinetic profile in end-stage renal disease. Hence, the use of vitamin K inhibitors is currently the only pharmacological option for stroke prevention in dialysis patients with atrial fibrillation, leaving the clinicians in a management conundrum.
2.Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
Yoshimura A1, Iriki Y1, Ichiki H1, Oketani N2, Okui H1, Maenosono R3, Namino F3, Miyata M1, Ohishi M1. J Cardiol. 2016 Apr 27. pii: S0914-5087(16)30041-7. doi: 10.1016/j.jjcc.2016.03.014. [Epub ahead of print]
BACKGROUND: We previously reported that dabigatran increased the risk of microthromboembolism and hemopericardium compared with warfarin. The safety of non-vitamin-K-antagonist oral anticoagulants (NOACs) in the periprocedural use of atrial fibrillation (AF) ablation is controversial. This study aimed to compare the incidence of asymptomatic cerebral microthromboembolism and hemopericardium in AF ablation among periprocedural use of rivaroxaban, apixaban, and warfarin.
3.Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R1, Kavtaradze A1, Gupta A2, Ghosh RK3. Int J Cardiol. 2016 Mar 28;214:292-298. doi: 10.1016/j.ijcard.2016.03.056. [Epub ahead of print]
The Vitamin K antagonist warfarin was the only oral anticoagulant available for decades for the treatment of thrombosis and prevention of thromboembolism until Direct Oral Anticoagulants (DOACs); a group of new oral anticoagulants got approved in the last few years. Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade. DOACs have many advantages over warfarin. However, the biggest drawback of DOACs has been the lack of specific antidotes to reverse the anticoagulant effect in emergency situations. Activated charcoal, hemodialysis, and activated Prothrombin Complex Concentrate (PCC) were amongst the nonspecific agents used in a DOAC associated bleeding but with limited success. Idarucizumab, the first novel antidote against direct thrombin inhibitor dabigatran was approved by US FDA in October 2015. It comprehensively reversed dabigatran-induced anticoagulation in a phase I study.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Factor Xa Products

CAS 280118-23-2 BMS-740808

(CAS: 280118-23-2)

BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa with Ki of 0.03 nM.

CAS 193153-04-7 Otamixaban

(CAS: 193153-04-7)

Otamixaban, is a novel, selective, rapid acting, competitive, reversible and direct fXa inhibitor of the β-aminoester class. It was in Phase-III clinical develo...

CAS 480449-71-6 Edoxaban TsOH salt

Edoxaban TsOH salt
(CAS: 480449-71-6)

Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.

CAS 536748-46-6 Eribaxaban

(CAS: 536748-46-6)

Eribaxaban is an orally active inhibitor of coagulation factor Xa (activated factor X). It has anticoagulant activity and is used as an anticoagulant drug. It i...

CAS 330942-05-7 betrixaban

(CAS: 330942-05-7)

Betrixaban is a long-acting anticoagulant used for the treatment of venous thromboembolism (VTE) caused by limited mobility or some other factors in adult patie...

CAS 288079-93-6 BMS-344577

(CAS: 288079-93-6)

BMS-344577 is aroylguanidine-based lactam derivative, which is a potent FXa inhibitor (FXa IC(50)=4 nM, EC(2xPT)=7 microM).

CAS 366789-02-8 Rivaroxaban

(CAS: 366789-02-8)

Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembol...

CAS 503612-47-3 Apixaban

(CAS: 503612-47-3)

Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a...

Chemical Structure

CAS 503612-47-3 Apixaban

Quick Inquiry

Verification code

Featured Items